From its tiny origins in combo HIV, Leronlimab quickly stretched its borders to HIV monotherapy, then turned its sights onto mTNBC before sweeping brutally across the broad plains of cancer. GvHD was put on notice, and then NASH, and all manner of autoimmune disorders. And when the world was overrun by Covid-19, it charged fearlessly into the fray, promising that influenza and all of pneumonia would soon be under its sway!

-from The Annals of Leronlimab